PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

10/805,919

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Application Number** 

TRANSMITTAL	Filing Date		March 22, 2004			
JUN 2 7 2005 TORM		First Named Inventor		Stanley T. Crooke		
		Art Unit		To Be Dete	rmined	
sed for all correspondence after	initial filing)	Examiner Name		To Be Dete	rmined	
Total Number of Pages in This Submiss	ion	Attorney Docket Nun	nber	ISIS0003-1	03 (ISPH-0522US.D2)	フ
	ENCLO	SURES (check all that a	apply)			
Fee Transmittal Form	☐ Drawing(s	s)		After Allowance	Communication to TC	
Fee Attached	Licensing	-related Papers	_	Appeal Commu of Appeals and	unication to Board I Interferences	
Amendment / Reply	Petition				inication to TC Brief, Reply Brief)	
After Final		Convert to a al Application		Proprietary Info	ormation	
Affidavits/declaration(s)		Attorney, Revocation f Correspondence		Status Letter		
Extension of Time Request	Terminal	Disclaimer		Other Enclosu please identify b		
Express Abandonment Request		or Refund			and PTO SB/08b (3 pp.); (17 14) References Enclosed.	7
Supplemental Information Disclosure Statement		ber of CD(s)				
Certified Copy of Priority Document(s)	Remarks					
Reply to Missing Parts/ Incomplete Application						
Reply to Missing Parts under 37 CFR1.52 or 1.53						
SIG	NATURE OF	APPLICANT, ATTORI	NEY, O	R AGENT		
<sup>'</sup> Firm	Cozen O'Conno	or				
Signature	Pa	el L	0			
Printed Name Paul K. Legaa		d, Ph.D.				
Date	23 JUA		Reg. No.	38,534		
	CERTIFICA	TE OF TRANSMISSION	ON/MAI	LING		
I hereby certify that this corresponder Service with sufficient postage as fi Alexandria, VA 22313-1450 on the dat	rst class mail	in an envelope address	USPTC ed to: (	or deposited Commissioner	with the United States Pos for Patents, P.O. Box 14	stal 50,
Signature	21/	RO			•	
Typed or printed name Paul K t	egaard Ph D	Reg. No. 38.534		Date	WITUNE ZONT	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUN 2 7 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Stanley T. Crooke and Hongjiang Wu

Serial No.: 10/805,919

Group Art Unit: To Be Determined

Filing Date: March 22, 2004

**Examiner: To Be Determined** 

For: Human RNase III and Compositions and Uses Thereof

I certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.

On 23 JUNE VOST

Paul K. Legaard, Ph.D., Registration No. 38,534

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

I his S	Supplemental Information Disclosure Statement is being filed:
	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in
	37 C.F.R. § 1.491 of the international application.

before the mailing date of a first Office Action on the merits.

	mailin	and the mailing date of a first Office Action on the merits, but before the ag date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of vance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
		or
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
		No fee is owed by the applicant(s).
	Staten Final C.F.R	ordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with $\square$ the first or $\square$ second After Submission, and accordingly is accompanied by the Statement under 37 . § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.
	Notice Issue	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a e of Allowance under 37 C.F.R. § 1.311, but before the payment of the Fee, and accordingly is accompanied by the Statement under 37 C.F.R. $V(e)$ , (see "Statement," and "Fees" below).
$\boxtimes$	attach	es of the references (except the U.S. Patent documents) listed on the ned PTO Forms SB/08a and SB/08b, formerly known as PTO Form are enclosed.
EXCI	EPT TI	HAT:
		In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

	If any of the foregoing publications are not available to the Examiner.  Applicant will endeavor to supply copies at the Examiner's request.
Stater	nent under 37 C.F.R. § 1.97(e)
	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
Fees	
$\boxtimes$	No Fee is owed by the applicant(s).
	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
Metho	od of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
$\boxtimes$	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
	No fee or Statement is required under 37 C.F.R. § 1.97(b).
	Respectfully submitted,
	Paul K. Legaard, Ph.D. Registration No. 38,534

Dated: 23 June 2005

COZEN O'CONNOR, P.C. 1900 Market Street, 5<sup>th</sup> Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 701-2013 - Facsimile

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Papilovork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1445 VPTO				Complete if Known			
				Application Number	10/805,919		
INFO	RMATION	DIS	CLOSURE	Filing Date	March 22, 2004		
STA	<b>TEMENT B</b>	ΥΑ	PPLICANT	First Named Inventor	Stanley T. Crooke		
				Art Unit	To Be Determined		
	(Use as many she	eets as	necessary)	Examiner Name	To Be Determined		
Sheet	1	of	3	Attorney Docket Number	ISIS0003-103 (ISPH-0522US.D2)		

JUN 2 7 2005

			U.S. PATENT D	OCUMENTS		
Examiner	Cito	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	Cite No. <sup>1</sup>	Number - Kind Code <sup>2</sup> (if known)		Cited Document	Passages or Relevant Figures Appear	
	AL	US-6,506,559	01-14-2003	Fire et al.	·	
	AM	US-5,804,683	09-08-1998	Usman et al.	-	
	AN	US-5,891,683	04-06-1999	Usman et al.		
		US-				
		US-				
		US-			*	
		US-			-	
		US-			2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
		US-				

-	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY  Name of Patentee or Applicant of Cited Document  Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Name of Patentee or		
Initials*	No.1	Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )		T⁵		
	AO	WO 94/01550	01-20-1994	Hybridon		
	AP	WO 92/07065	04-30-1992	Max-Planck- Gesellschaft		
	<del>                                     </del>					

Examiner Signature	Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for torn 1449 10

JUN 2 7 2005

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet of 3

	Complete if Known
Application Number	10/805,919
Filing Date	March 22, 2004
First Named Inventor	Stanley T. Crooke
Art Unit	To Be Determined
Examiner Name	To Be Determined
Attorney Docket Number	ISIS0003-103 (ISPH-0522US.D2)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AQ	Arya et al., "Inhibition Of RNA Directed DNA Polymerase Of Murine Leukemia Virus By 2'-O-Alkylated Polyadenylic Acides," <i>Biochem. Biophys. Res. Commun.</i> , 1974, Vol. 59, No. 2, pp. 608-615.	
	AR	Arya et al., "Inhibition Of Synthesis Of Murine Leukemia Virus In Cultured Cells By Polyribonucleotides And Their 2'-O-Alkyl Derivatives," <i>Molecular Pharmacology</i> , 1976, Vol. 12, pp. 234-241.	
	AS	DeClercq et al., "Influence Of Various 2- And 2'-Substituted Polyadenyl Acids On Murine Leukemia Virus Reverse Transcriptase," <i>Cancer Letters</i> , 1979, Vol. 7, pp. 27-37.	
	АТ	Hobbs et al., "Polynucleotides Containing 2'-Amino 2'-deoxyribose And 2'-Azido-2'-deoxyriboes," <i>Biochem.</i> , 1973, Vol. 12, pp. 5138-5145.	
	AU	Hobbs et al., "Poly 2'-Deoxy-2'-Aminouridylic Acid," Biochem. Biophys. Res. Commun, 1972, Vol. 46, No. 4, pp. 1509-1515.	
	AV	Hobbs et al., "Polynucleotides Containing 2'-Chloro-2'-deoxyribose," <i>Biochem.</i> , 1972, Vol. 11, pp. 4336-4344.	
	AW	Pieken et al., "Kinetic Characterization Of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> , 1991, Vol. 253, pp. 314-317.	
	AX	Pilet et al., "Structural Parameters Of Single And Double Helical Polyribonucleotides," Biochem. Biophys Res. Commun, 1973, Vol. 52, No. 2, pp. 517-523.	
	AY	Rottman et al., "Polynucleotides Containing 2'-O-Methyladenosine. I. Synthesis By Polynucleotide Phosphorylase," <i>Biochem</i> , 1968, Vol. 7, pp. 2634-2641.	
	AZ	Rottman et al., "Polymers Containing 2'-O-Methylnucleotides. II. Synthesis Of Heteropolymers," <i>Biochem</i> , 1969, Vol. 8, No. 11, pp. 4354-4361.	
	ВА	Wincott et al., "Synthesis, Deprotection, Analysis And Purification Of RNA And Ribozymes," Nucl. Acids Res., 1995, Vol. 23, No. 14, pp. 2677-2684.	

1	Examiner	Date	
Į	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/805,919 INFORMATION DISCLOSURE Filing Date March 22, 2004 STATEMENT BY APPLICANT First Named Inventor Stanley T. Crooke Art Unit To Be Determined (Use as many sheets as necessary) Examiner Name To Be Determined Sheet Attorney Docket Number ISIS0003-103 (ISPH-0522US.D2) of

JUN 2 7 2005

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	ВВ	Zmudzka et al., "Poly 2'-OMethylcytidylic Acid And The Role Of The 2'-Hydroxyl In Polynucleotide Structure," Biochem Biophys. Res. Commun., 1969, Vol. 37, No. 6, pp. 895-901.	
			<u> </u>
		·	
	<u> </u>	I	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.